Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Interventional × Lamotrigine × Clear all

Phase

Phase 3 1 Phase 2/3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Noonan Syndrome 1 Neurofibromatosis 1 1 Cognition Disorders 1

Interventions

Cisplatin 1267 Carboplatin 1173 Cyclophosphamide 1129 Gemcitabine 1030 Bevacizumab 1011 Paclitaxel 1006 Radiotherapy 998 Docetaxel 931 pembrolizumab 864 Oxaliplatin 777 Capecitabine 758 Fluorouracil 717 Rituximab 622 Doxorubicin 564 Dexamethasone 560 Nivolumab 555 Etoposide 555 Irinotecan 534 Leucovorin 493 Pemetrexed 423 Drug Therapy 403 Cetuximab 398 Cytarabine 396 Trastuzumab 391 Filgrastim 374 Magnetic Resonance Spectroscopy 365 Prednisone 359 Lenalidomide 342 Bortezomib 339 Temozolomide 331

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03504501 2023-11-30

SynCoRAS

Technical University of Munich

Phase 2 Terminated

Cognition Disorders, Neurofibromatosis 1, Noonan Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡